Trial Profile

Phase I/II of Durvalumab (MEDI4736) + Tremelimumab + Stereotactic Body Radiotherapy for Metastatic Head and Neck Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 10 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
Indications Carcinoma; Head and neck cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

28 Jun 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
28 Jun 2024 Planned primary completion date changed from 31 Jul 2023 to 31 Jul 2024.
06 Jun 2023 Primary endpoint has been met, (Progression Free Survival (PFS), as per Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com